Arrowhead Pharmaceuticals, Inc.(ARWR)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
ARWR | 8.32 B | - | 171.00% | -47.79% | -$2.29 | -55.21% | 2.96x | 0.00% | $95.49 | $36.57 |
SMMT | 12.84 B | - | - | 0.00% | -$1.08 | -192.51% | 0.03x | 0.00% | $29.23 | $12.07 |
BMRN | 10.93 B | 152.54x | 19.90% | 2.14% | $0.37 | 1.18% | 0.66x | 0.00% | $70.98 | $49.26 |
MDGL | 10.80 B | - | 71.20% | -25.32% | -$13.07 | -53.31% | 0.66x | 0.00% | $615.00 | $393.61 |
IONS | 7.54 B | - | -40.70% | -64.66% | -$3.51 | -105.50% | 4.98x | 0.00% | $86.74 | $42.08 |
Peer Valuation & Performance Analysis
Peer group analysis for Arrowhead Pharmaceuticals, Inc. (ARWR) compared to its primary competitors (including SMMT, BMRN, MDGL) reveals distinct metrics. ARWR trades at a valuation discount relative to its competitors, with a P/E ratio of -25.7x versus the peer average of 22.2x (representing a 216% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, ARWR's revenue growth of 171.0% exceeds the peer average of 16.8%, highlighting its competitive strength and market share gains. Additionally, its net margin of -47.8% is below the peer average of -22.0%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• ARWR ranks #0 in P/E ratio, #1 in revenue growth, and #4 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-21 | $59.42 | $60.46 | $58.82 | $58.84 | 1,371,453 | -0.14% |
| 2026-10-20 | $56.93 | $59.57 | $56.91 | $58.92 | 1,742,300 | +2.95% |
| 2026-10-19 | $56.96 | $57.30 | $56.05 | $57.23 | 1,647,000 | +2.38% |
| 2026-10-16 | $58.45 | $58.45 | $55.83 | $55.90 | 1,772,800 | -4.44% |
| 2026-10-15 | $58.50 | $59.40 | $57.40 | $58.50 | 2,009,600 | +0.22% |
| 2026-10-14 | $58.48 | $60.53 | $57.15 | $58.37 | 4,160,100 | +0.41% |
| 2026-10-13 | $60.04 | $60.73 | $58.08 | $58.13 | 2,260,400 | -4.28% |
| 2026-10-12 | $62.49 | $62.50 | $60.48 | $60.73 | 1,194,400 | -3.22% |
| 2026-10-09 | $60.72 | $62.99 | $60.44 | $62.75 | 2,765,700 | +3.31% |
| 2026-10-08 | $60.54 | $61.13 | $59.20 | $60.74 | 1,784,700 | -1.20% |
| 2026-10-07 | $61.63 | $62.75 | $60.78 | $61.48 | 1,819,200 | -0.10% |
| 2026-10-06 | $62.86 | $63.19 | $60.56 | $61.54 | 1,675,500 | -1.30% |
| 2026-10-05 | $64.76 | $64.76 | $62.22 | $62.35 | 2,249,400 | -2.87% |
| 2026-10-02 | $65.57 | $66.16 | $63.99 | $64.19 | 1,487,600 | -0.93% |
| 2026-10-01 | $65.00 | $65.75 | $64.50 | $64.79 | 1,521,700 | -1.01% |
Explore More Analysis for ARWR
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.